The biochemical characterisation of the proteolytic pathways that constitute blood
coagulation was one of the most relevant achievements in biomedical research during the …

Factor V (FV) is a regulator of both pro‐and anticoagulant pathways. It circulates as a single‐
chain procofactor, which is activated by thrombin or FXa to FVa that serves as cofactor for …

Safe and effective antithrombotic therapy requires understanding of mechanisms that
contribute to pathological thrombosis but have a lesser impact on hemostasis. We found that …

A paradigm of venom research is adaptive evolution of toxins as part of a predator-prey
chemical arms race. This study examined differential co-factor dependence, variations …

Tissue factor pathway inhibitor (TFPI), the main inhibitor of initiation of coagulation, exerts an
important anticoagulant role through the factor Xa (FXa)-dependent inhibition of tissue …

The increased risk of cardiovascular events in older men is multifactorial, but the significant
reduction of testosterone levels has been involved. As this hormone regulates the …

Essentials• Protein S is a cofactor of activated protein C (APC) and tissue factor pathway
inhibitor (TFPI).• There are no assays to quantify separate APC and TFPI cofactor activities of …

Introduction Increased visceral adipose tissue (VAT) has been shown to be associated with
the development of insulin resistance, type 2 diabetes, stroke, and ischemic heart disease. It …

Abstract Hereditary Protein S (PS) deficiency is a rare coagulation disorder associated with
an increased risk of venous thrombosis (VT). The PS Heerlen (PSH) mutation is a rare …

Background Only 10% of plasma TFPIα (TFPI) exists in the full length form, the rest circulates
as a C-terminally truncated form. However, blood platelets exclusively contain full length …